HK InnoN K-Cap Officially Releases India, World's 4th-largest market size for peptic ulcer drugs
Sep 17, 2025
|
K-Cap was approved for the treatment of ▲ erosive gastroesophageal reflux disease ▲ non erosive gastroesophageal reflux disease ▲ gastric ulcer in May under the name 'PCAB 50 mg' in India. In 2022, HKINOEN signed a contract with Dr. Reddy to export finished K-cap tablets to six emerging countries with India.
India's peptic ulcer drug market is about 1.52 trillion won as of 2024, the fourth largest in the world after China, the United States and Japan. About 38% of India's population is known to have gastroesophageal reflux disease.
M.V. Ramana, President of India and Emerging Countries, Dr. Reddy said, "This P-Cap launch is the fruit of Dr. Reddy's efforts to provide innovative treatment options in the field of gastroesophageal reflux disease. Dr. Reddy has established a strong and trusted position in the field through its diverse portfolio, including Omez® (Omeprazole), Razo® (Laveprazole), and Vono™ (Bonofrazan). By increasing the synergy of our partnership with HKINOEN, we will provide innovative new drugs to bridge the gastroesophageal reflux disease management gap and improve patient accessibility."
"We are very pleased that K-Cap will enter India, one of the major pharmaceutical markets in the world," said Kwak Dal-won, CEO of HKINOEN. "We look forward to establishing K-Cap as a global innovative new drug representing the P-CAB family in the future, providing new treatment options for Indian patients, just like the Indian product name 'PCAB(P-CAB)"
This article was translated by Naver AI translator.
